Drug Trial Radar · NCT04840394
Clinical Study of BDB018: Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Nov 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1
Actual
Start
Jun 22, 2021
Primary completion
Mar 31, 2024
Study completion Sep 30, 2024
Sponsor
- Lead sponsor
- Eikon TherapeuticsIndustry
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Apr 12, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 1 Open-label Dose Escalation Trial of BDB018 in Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors
Conditions
- Tumor, Solid
Interventions
BDB018Drug
BDB018 is an immunotherapy agent.
PembrolizumabDrug
Pembrolizumab is a potent humanized monoclonal antibody with high specificity of binding to the PD 1 receptor. Pembrolizumab has an acceptable preclinical safety profile and is approved as an IV therapy for a variety of advanced malignancies.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and Tolerability: incidence of adverse events and any dose limiting toxicityTime frame: Up to 30 months
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Florida Cancer Specialists
Sarasota, Florida
START MidWest
Grand Rapids, Michigan
START
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.